Skip to main content

Advertisement

SpringerLink
Log in

Considering metabolic issues when initiating HIV therapy

  • Published:
Current HIV/AIDS Reports Aims and scope Submit manuscript

    We’re sorry, something doesn't seem to be working properly.

    Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.

Abstract

Patients with HIV infection and their clinicians are increasingly considering the risk of metabolic complications when choosing HIV therapies. Fear of the potential metabolic consequences of antiretroviral agents may lead some to delay HIV therapy and threaten medication adherence once treatment is initiated. Until recently, there has been limited objective study of the relative contributions of specific antiretrovirals and particular combinations of these drugs to dyslipidemia and body fat changes; in lieu of data, unsupported perceptions regarding the links between therapies and these metabolic complications have predominated. Over the past year, a number of comparative clinical trials have clarified the association between exposure to antiretrovirals and lipid and fat disorders and, in some cases, have yielded results that challenge our perceptions regarding the causes of these complications.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Bacchetti P, Gripshover B, Grunfeld C, et al.: Fat distribution in men with HIV infection. J Acquir Immune Defic Syndr 2005, 40:121–131.

    Article  PubMed  Google Scholar 

  2. Schambelan M, Benson CA, Carr A, et al.: Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002, 31:257–275.

    PubMed  Google Scholar 

  3. Carr A, Miller J, Law M, et al.: A syndrome of lipoatrophy, lactic acidaemia and liver dysfunction associated with HIV nucleoside analogue therapy: contribution of protease inhibitor-related lipodystrophy syndrome. AIDS 2000, 14:F25–32.

    Article  PubMed  CAS  Google Scholar 

  4. Wohl DA, McComsey G, Tebas P, et al.: Current concepts in the diagnosis and management of metabolic complications of HIV infection and its therapy. Clin Infect Dis 2006, 43:645–653.

    Article  PubMed  CAS  Google Scholar 

  5. Sax PE, Kumar P: Tolerability and safety of HIV protease inhibitors in adults. J Acquir Immune Defic Syndr 2004, 37:1111–1124.

    Article  PubMed  CAS  Google Scholar 

  6. Ammassari A, Antinori A, Cozzi-Lepri A, et al.: Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002, 31:S140–S144.

    PubMed  Google Scholar 

  7. Marin A, Casado JL, Aranzabal L, et al.: Validation of a specific questionnaire on psychological and social repercussions of the lipodystrophy syndrome in HIV-infected patients. Qual Life Res 2006, 15:767–775.

    Article  PubMed  Google Scholar 

  8. Mulligan K, Parker RA, Komarow L, et al.: Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial. J Acquir Immune Defic Syndr 2006, 41:590–597.

    Article  PubMed  CAS  Google Scholar 

  9. Cameron DW, da Silva B, Arribas J, et al.: Significant sparing of peripheral lipoatrophy by HIV treatment with LPV/r + ZDV/3TC induction followed by LPV/R monotherapy compared with EFV + ZDV/3TC [abstract 44LB]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.

  10. Joly V, Flandre P, Meiffredy V, et al.: Increased risk of lipoatrophy under stavudine in HIV-1 infected patients: results of a substudy from a comparative trial. AIDS 2002, 16:2447–2457.

    Article  PubMed  CAS  Google Scholar 

  11. Mallal SA, John M, Moore CB, et al.: Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 2000, 14:1309–1316.

    Article  PubMed  CAS  Google Scholar 

  12. Gallant JE, Staszewski S, Pozniak AL, et al.: Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. JAMA 2004, 292:191–201.

    Article  PubMed  CAS  Google Scholar 

  13. Carr A, Workman C, Smith DE, et al.: Abacavir substitution for thymidine nucleoside analogues in HIV-infected patients with lipoatrophy: a randomized controlled open-label multicenter 24 week study. JAMA 2002, 288:207–215.

    Article  PubMed  CAS  Google Scholar 

  14. Moyle G, Sabin C, Cartledge J, et al.: A 48 week, randomized, open-label comparative study of tenofovir DF vs. abacavir as substitutes for a thymidine analog in persons with lipoatrophy and sustained virological suppression on HAART [abstract 44LB]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  15. Milinkovic A, Lopez S, Vidal S, et al.: A randomized open study comparing the effect of reducing stavudine dose vs switching to tenofovir on mitochondrial function, metabolic parameters, and subcutaneous fat in HIV-infected patients receiving antiretroviral therapy containing stavudine [abstract 857]. Paper presented at the 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA; February 22–25, 2005.

  16. McComsey GA, Paulsen DM, Lonergan JT, et al.: Improvements in lipoatrophy, mitochondrial DNA levels and fat apoptosis after replacing stavudine with abacavir or zidovudine. AIDS 2005, 19:15–23.

    Article  PubMed  CAS  Google Scholar 

  17. Brinkman K, Smeitink JA, Romijn JA, et al.: Mitochondrial toxicity induced by nucleoside analogue reverse transcriptase inhibitors is a key factor in the pathogenesis of antiretroviral therapy lipodystrophy. Lancet 1999, 354:1112–1115.

    Article  PubMed  CAS  Google Scholar 

  18. Lee H, Hanes J, Johnson KA: Toxicity of nucleoside analogues used to treat AIDS and the selectivity of the mitochondrial DNA polymerase. Biochemistry 2003, 42:14711–14719.

    Article  PubMed  CAS  Google Scholar 

  19. Nolan D, Hammond E, James I, et al.: Contribution of nucleoside-analogue reverse transcriptase inhibitor therapy to lipoatrophy from the population to the cellular level. Antivir Ther 2003, 8:617–626.

    PubMed  CAS  Google Scholar 

  20. Pozniak AL, Gallant JE, Dejesus E, et al.: Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes — a 96-week analysis. J Acquir Immune Defic Syndr 2006, 43:535–540.

    PubMed  CAS  Google Scholar 

  21. Dubé M, Komarow L, Mulligan K, et al.: DEXA outcomes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz or both plus dual nucleosides: long-term results from A5005s, a substudy of ACTG 384 [abstract WEPE0167]. Paper presented at the XVI International AIDS Conference. Toronto, Canada; August 13–18, 2006.

  22. Haubrich RH, Riddler S, DiRienzo G, et al.: Metabolic outcomes of ACTG 5142: a prospective, randomized, phase III trial of NRTI-, PI-, and NNRTI-sparing regimens for initial treatment of HIV-1 infection [abstract 38]. Presented at the 14th Conference on Retroviruses and Opportunistic Infections. Los Angeles, CA; February 25–28, 2007.

  23. Carr A, Samaras K, Burton S, et al.: A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998, 12:F51–58.

    Article  PubMed  CAS  Google Scholar 

  24. Saint-Marc T, Partisani M, Poizot-Martin I, et al.: Fat distribution evaluated by computed tomography and metabolic abnormalities in patients undergoing antiretroviral therapy: preliminary results of the LIPOCO study. AIDS 2000, 14:37–49.

    Article  PubMed  CAS  Google Scholar 

  25. Carr A, Cooper DA: Images in clinical medicine. Lipodystrophy associated with an HIV-protease inhibitor. N Engl J Med 1998, 339:1296.

    Article  PubMed  CAS  Google Scholar 

  26. Jemsek JG, Arathoon E, Arlotti M, et al.: Body fat and other metabolic effects of atazanavir and efavirenz, each administered in combination with zidovudine plus lamivudine, in antiretroviral-naive HIV-infected patients. Clin Infect Dis 2006, 42:273–280.

    Article  PubMed  CAS  Google Scholar 

  27. Mallon PW, Miller J, Cooper DA, Carr A: Prospective evaluation of the effects of antiretroviral therapy on body composition in HIV-1-infected men starting therapy. AIDS 2003, 17:971–979.

    Article  PubMed  CAS  Google Scholar 

  28. Dube MP, Parker RA, Tebas P, et al.: Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides. AIDS 2005, 19:1807–1818.

    Article  PubMed  CAS  Google Scholar 

  29. Hicks C, DeJesus E, Sloan L, et al.: Efficacy and safety of once-daily boosted fosamprenavir/ritonavir with abacavir/lamivudine fixed dose combination in antiretroviral naive HIV-1 infected patients: 24-week results from COL100758 [abstract P2]. Presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12–16, 2006.

  30. Tashima K, Stryker R, Skeist D, et al.: Lack of clinical lipodystrophy in patients receiving efavirenz + NRTI in study 006 [abstract 1304]. Paper presented at the 39th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 26–29, 1999.

  31. Currier J, Carpenter C, Daar E, et al.: Identifying and managing morphologic complications of HIV and HAART. AIDS Read 2002, 12:114–119, 124–125.

    PubMed  Google Scholar 

  32. Grunfeld C, Kotler DP, Hamadeh R, et al.: Hypertriglyceridemia in the acquired immunodeficiency syndrome. Am J Med 1989, 86:27–31.

    Article  PubMed  CAS  Google Scholar 

  33. Grinspoon S, Carr A: Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 2005, 352:48–62.

    Article  PubMed  CAS  Google Scholar 

  34. Riddler SA, Smit E, Cole SR, et al.: Impact of HIV infection and HAART on serum lipids in men. JAMA 2003, 289:2978–2982.

    Article  PubMed  CAS  Google Scholar 

  35. van Leth F, Phanuphak P, Stroes E, et al.: Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med 2004, 1:e19.

    Article  PubMed  CAS  Google Scholar 

  36. Gallant JE, DeJesus E, Arribas JR, et al.: Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006, 354:251–260.

    Article  PubMed  CAS  Google Scholar 

  37. Eron J Jr, Yeni P, Gathe J Jr, et al.: The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 2006, 368:476–482.

    Article  PubMed  CAS  Google Scholar 

  38. Montes ML, Pulido F, Barros C, et al.: Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors. J Antimicrob Chemother 2005, 55:800–804.

    Article  PubMed  CAS  Google Scholar 

  39. Malan N, Krantz E, David N, et al.: Efficacy and safety of atazanavir-based therapy in antiretroviral naive HIV-1 infected subjects, both with and without ritonavir: 48-week results from AI424-089 [abstract 107LB]. Presented at the 13th Conference on Retroviruses and Opportunistic Infections. Denver, CO; February 5–8, 2006.

  40. Martinez E, Domingo P, Galindo MJ, et al.: Risk of metabolic abnormalities in patients infected with HIV receiving antiretroviral therapy that contains lopinavir-ritonavir. Clin Infect Dis 2004, 38:1017–1023.

    Article  PubMed  CAS  Google Scholar 

  41. Teppler H, Azrolan N, Chen J, Nguyen BY, for the Protocol 004 Study Group: Differential effect of MK-0518 and efavirenz on serum lipids and lipoproteins in antiretroviral therapy (ART)-naive patients [abstract H-0256a]. Paper presented at the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA; September 27–30, 2006.

  42. Shafran SD, Mashinter LD, Roberts SE: The effect of low-dose ritonavir monotherapy on fasting serum lipid concentrations. HIV Med 2005, 6:421–425.

    Article  PubMed  CAS  Google Scholar 

  43. Purnell JQ, Zambon A, Knopp RH, et al.: Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000, 14:51–57.

    Article  PubMed  CAS  Google Scholar 

  44. Smith K, Weinberg W, DeJesus E, et al.: Once-daily boosted fosamprenavir (FPV/r) or atazanavir (ATZ/r) with tenofovir/emtricitabine in antiretroviral naive HIV-1 infected patients: 24-week results from COL103952 (ALERT) [abstract P1]. Presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12–16, 2006.

  45. Slim J, Avihingsanon A, Ruxrungtham K, et al.: Saquinavir BID vs lopinavir plus emtricitabine/tenofovir QD in ARV-naive HIV-1 infected patients: GEMINI study [abstract PL2.5]. Paper presented at the 8th International Congress on Drug Therapy in HIV Infection. Glasgow, Scotland; November 12–16, 2006.

Download references

Author information

Authors and Affiliations

  1. The University of North Carolina, 130 Mason Farm Road, Chapel Hill, NC, 27599, USA

    David Alain Wohl MD

Authors
  1. David Alain Wohl MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David Alain Wohl MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wohl, D.A. Considering metabolic issues when initiating HIV therapy. Curr HIV/AIDS Rep 4, 119–125 (2007). https://doi.org/10.1007/s11904-007-0018-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11904-007-0018-5

Keywords

Search

Navigation